This conclusion followed the treatment of KRAS mutant CRC cells with a glycolysis inhibitor, which caused restoration of AMPK phosphorylation and anti-EGFR sensitization in CRC cells. The gene discussed is KRAS; the disease is colorectal carcinoma.